Related references
Note: Only part of the references are listed.2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Risk of cardiovascular events in patients with hypertriglyceridaemia: A review of real-world evidence
Peter P. Toth et al.
DIABETES OBESITY & METABOLISM (2020)
Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies
Patrick R. Lawler et al.
EUROPEAN HEART JOURNAL (2020)
Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics
William E. Boden et al.
EUROPEAN HEART JOURNAL (2020)
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
Jan Boren et al.
EUROPEAN HEART JOURNAL (2020)
Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipoproteins in type II diabetic subjects
Marja-Riitta Taskinen et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2020)
Apolipoprotein B48 metabolism in chylomicrons and very low-density lipoproteins and its role in triglyceride transport in normo- and hypertriglyceridemic human subjects
E. Bjornson et al.
JOURNAL OF INTERNAL MEDICINE (2020)
Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease
Brian A. Ference et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)
Investigation of human apoB48 metabolism using a new, integrated non-steady-state model of apoB48 and apoB100 kinetics
E. Bjornson et al.
JOURNAL OF INTERNAL MEDICINE (2019)
Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia
Martin Adiels et al.
DIABETES OBESITY & METABOLISM (2019)
Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study
Robert S. Rosenson et al.
DIABETOLOGIA (2019)
The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation
Jean-Charles Fruchart et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association
Ann C. Skulas-Ray et al.
CIRCULATION (2019)
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies
Norbert Stefan et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Dietary Fructose and the Metabolic Syndrome
Marja-Riitta Taskinen et al.
NUTRIENTS (2019)
Effects of APOC3 Heterozygous Deficiency on Plasma Lipid and Lipoprotein Metabolism
Gissette Reyes-Soffer et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
Low-Grade Inflammation in the Association between Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis: A Study of More Than 115000 Individuals from the General Population
Signe E. J. Hansen et al.
CLINICAL CHEMISTRY (2019)
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism
Dick C. Chan et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2018)
Liraglutide Reduces Postprandial Hyperlipidemia by Increasing ApoB48 (Apolipoprotein B48) Catabolism and by Reducing ApoB48 Production in Patients With Type 2 Diabetes Mellitus
Bruno Verges et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2018)
An Integrated Understanding of the Rapid Metabolic Benefits of a Carbohydrate-Restricted Diet on Hepatic Steatosis in Humans
Adil Mardinoglu et al.
CELL METABOLISM (2018)
Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial
Antonio J. Vallejo-Vaz et al.
CIRCULATION (2018)
Molecular Actions of PPARα in Lipid Metabolism and Inflammation
Nadia Bougarne et al.
ENDOCRINE REVIEWS (2018)
Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps
Andrea Baragetti et al.
PHARMACOLOGICAL RESEARCH (2018)
Recent Advances in Triacylglycerol Mobilization by the Gut
Changting Xiao et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2018)
ANGPTL8: An important Regulator in Metabolic Disorders
Mengdie Luo et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial
Stephen J. Nicholls et al.
CLINICAL CARDIOLOGY (2018)
FAMILIAL CHYLOMICRONEMIA SYNDROME: A CLINICAL GUIDE FOR ENDOCRINOLOGISTS
James M. Falko
ENDOCRINE PRACTICE (2018)
Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study
Aruna D. Pradhan et al.
AMERICAN HEART JOURNAL (2018)
Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans
Gissette Reyes-Soffer et al.
CIRCULATION (2017)
Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism
Gerald F. Watts et al.
CIRCULATION (2017)
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Brian A. Ference et al.
EUROPEAN HEART JOURNAL (2017)
Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review
Jan Oscarsson et al.
LIPIDS IN HEALTH AND DISEASE (2017)
Angiopoietin-like 3 in lipoprotein metabolism
Sander Kersten
NATURE REVIEWS ENDOCRINOLOGY (2017)
Increasing Lipolysis and Reducing Atherosclerosis
Alan R. Tall
NEW ENGLAND JOURNAL OF MEDICINE (2017)
HDL Cholesterol Metabolism and the Risk of CHD: New Insights from Human Genetics
Cecilia Vitali et al.
CURRENT CARDIOLOGY REPORTS (2017)
News on the molecular regulation and function of hepatic low-density lipoprotein receptor and LDLR-related protein 1
Bart van de Sluis et al.
CURRENT OPINION IN LIPIDOLOGY (2017)
Remnant Cholesterol Elicits Arterial Wall Inflammation and a Multilevel Cellular Immune Response in Humans
Sophie J. Bernelot Moens et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2017)
Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease New Insights From Epidemiology, Genetics, and Biology
Borge G. Nordestgaard
CIRCULATION RESEARCH (2016)
Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?
Marja-Riitta Taskinen et al.
CURRENT ATHEROSCLEROSIS REPORTS (2016)
Regulation of lipid metabolism by angiopoietin-like proteins
Wieneke Dijk et al.
CURRENT OPINION IN LIPIDOLOGY (2016)
Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2016)
Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?
Geesje M. Dallinga-Thie et al.
CURRENT CARDIOLOGY REPORTS (2016)
Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity Multicenter Tracer Kinetic Study
Jan Boren et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
New insights into the pathophysiology of dyslipidemia in type 2 diabetes
Marja-Riitta Taskinen et al.
ATHEROSCLEROSIS (2015)
The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia
Frank M. Sacks
CURRENT OPINION IN LIPIDOLOGY (2015)
Hypertriglyceridemia in the Genomic Era: A New Paradigm
Gary F. Lewis et al.
ENDOCRINE REVIEWS (2015)
Fasting Triglycerides Predict Recurrent Ischemic Events in Patients With Acute Coronary Syndrome Treated With Statins
Gregory G. Schwartz et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2015)
Effect of Dietary Fatty Acids on Human Lipoprotein Metabolism: A Comprehensive Update
Esther M. M. Ooi et al.
NUTRIENTS (2015)
Postprandial hypertriglyceridemia as a coronary risk factor
Jan Boren et al.
CLINICA CHIMICA ACTA (2014)
Plasma Apolipoprotein B-48 Transport in Obese Men: A New Tracer Kinetic Study in the Postprandial State
Annette T. Y. Wong et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Triglycerides and cardiovascular disease
Borge G. Nordestgaard et al.
LANCET (2014)
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Anders Berg Jorgensen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Omega-3 fatty acid ethyl ester supplementation decreases very-low-density lipoprotein triacylglycerol secretion in obese men
Annette T. Y. Wong et al.
CLINICAL SCIENCE (2013)
Postprandial Hypertriglyceridemia and Cardiovascular Disease: Current and Future Therapies
D. C. Chan et al.
CURRENT ATHEROSCLEROSIS REPORTS (2013)
Determinants of VLDL-triglycerides production
Soren Nielsen et al.
CURRENT OPINION IN LIPIDOLOGY (2012)
Plasma HDL cholesterol and risk of myocardial infarction reply
Benjamin F. Voight et al.
LANCET (2012)
Dual Metabolic Defects Are Required to Produce Hypertriglyceridemia in Obese Subjects
Marja-Riitta Taskinen et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
Apolipoprotein A-V; a potent triglyceride reducer
Stefan K. Nilsson et al.
ATHEROSCLEROSIS (2011)
TRIGLYCERIDE-RICH LIPOPROTEINS AND HIGH-DENSITY LIPOPROTEIN CHOLESTEROL IN PATIENTS AT HIGH RISK OF CARDIOVASCULAR DISEASE: EVIDENCE AND GUIDANCE FOR MANAGEMENT
M. J. Chapman et al.
ATHEROSCLEROSIS SUPPLEMENTS (2011)
Triglycerides and Cardiovascular Disease A Scientific Statement From the American Heart Association
Michael Miller et al.
CIRCULATION (2011)
Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective
Marshall Elam et al.
CURRENT OPINION IN LIPIDOLOGY (2011)
Up-regulation of hepatic low-density lipoprotein receptor-related protein 1: a possible novel mechanism of antiatherogenic activity of hydroxymethylglutaryl-coenzyme A reductase inhibitor Atorvastatin and hepatic LRP1 expression
Jae Hoon Moon et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2011)
Apolipoprotein C-III and the Metabolic Basis for Hypertriglyceridemia and the Dense Low-Density Lipoprotein Phenotype
Chunyu Zheng et al.
CIRCULATION (2010)
Lipoprotein subfractions and cardiovascular disease risk
Ronald M. Krauss
CURRENT OPINION IN LIPIDOLOGY (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion
Meenakshi Sundaram et al.
NUTRITION & METABOLISM (2010)
Major Lipids, Apolipoproteins, and Risk of Vascular Disease
The Emerging Risk Factors Collaboration*
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Expanding functions of lipoprotein receptors
Joachim Herz et al.
JOURNAL OF LIPID RESEARCH (2009)
Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome
Martin Adiels et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
Intestinal lipoprotein overproduction in insulin-resistant states
Khosrow Adeli et al.
CURRENT OPINION IN LIPIDOLOGY (2008)
Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia
Diane L. Tribble et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2008)
Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus
A. Hiukka et al.
DIABETOLOGIA (2007)
Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women
Borge G. Nordestgaard et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Metabolism of apoB lipoproteins of intestinal and hepatic origin during constant feeding of small amounts of fat
Chunyu Zheng et al.
JOURNAL OF LIPID RESEARCH (2006)
Why do omega-3 fatty acids lower serum triglycerides?
William S. Harris et al.
CURRENT OPINION IN LIPIDOLOGY (2006)
Effect of n-3 fatty acids on metabolism of apoB100-containing lipoprotein in type 2 diabetic subjects
K. Ouguerram et al.
BRITISH JOURNAL OF NUTRITION (2006)
Contributions of different fatty acid sources to very low-density lipoprotein-triacylglycerol in the fasted and fed states
BR Barrows et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Overproduction of large VLDL particles is driven by increased liver fat content in man
M Adiels et al.
DIABETOLOGIA (2006)
Plasma metabolism of apoB-containing lipoproteins in patients with hepatic lipase deficiency
IL Ruel et al.
ATHEROSCLEROSIS (2005)
Complete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 production
JS Millar et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Lipoprotein metabolism in subjects with hepatic lipase deficiency
M Tilly-Kiesi et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2004)
Phenotypes, genotypes and response to statin therapy
MJ Caslake et al.
CURRENT OPINION IN LIPIDOLOGY (2004)
Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity
JS Cohn et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome
GF Watts et al.
DIABETES (2003)
Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity
DC Chan et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2003)
Fat compartments and apolipoprotein B-100 kinetics in overweight-obese men
GF Watts et al.
OBESITY RESEARCH (2003)
New perspectives on atherogenesis role of abnormal triglyceride-rich lipoprotein metabolism
HN Ginsberg
CIRCULATION (2002)
Metabolic origins and clinical significance of LDL heterogeneity
KK Berneis et al.
JOURNAL OF LIPID RESEARCH (2002)
Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates
LF Forster et al.
ATHEROSCLEROSIS (2002)
Subendothelial retention of atherogenic lipoproteins in early atherosclerosis
K Skålén et al.
NATURE (2002)
Effect of dietary carbohydrate on triglyceride metabolism in humans
EJ Parks
JOURNAL OF NUTRITION (2001)
VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial
FM Sacks et al.
CIRCULATION (2000)
Effects of ApoE genotype on ApoB-48 and ApoB-100 kinetics with stable isotopes in humans
FK Welty et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2000)
Share Paper
